Biotechnology company Auxilius Pharma has announced a $4 million Series A financing round to accelerate the development of a chronic stable angina treatment.  AUX-001 has been designed by Auxilius as a once-daily formulation, designed to treat and prevent chronic stable angina. The candidate could become the first new innovative oral therapy for chronic stable angina […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!